DRREDDYDr. Reddy's Laboratories Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
Forensic screen of the latest filings
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹8698 Cr | ₹913 Cr | 13.84% | 10.50% | ₹11.10 | 10.9x |
| Q1 FY2027 | ₹8100 Cr | ₹436 Cr | 3.99% | 5.38% | ₹5.33 | 5.4x |
| Q4 FY2026 | ₹7546 Cr | ₹221 Cr | -2.31% | 2.93% | ₹2.65 | 2.8x |
| Q3 FY2026 | ₹8753 Cr | ₹1190 Cr | 15.61% | 13.59% | ₹14.53 | 17.3x |
| Q2 FY2026 | ₹8828 Cr | ₹1337 Cr | 17.05% | 15.14% | ₹16.18 | 20.2x |
| Q1 FY2026 | ₹8572 Cr | ₹1410 Cr | 19.80% | 16.45% | ₹17.04 | 23.9x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.